Alzheimer's Drugs Double Death Risk
Experts Say Anti-Dementia Drugs Are Dangerous, Overused
-
Anti-psychotic drugs commonly used to treat Alzheimer's disease may double a patient's chance of dying within a few years, according to a new study. (AP / CBS)
-
Play CBS Video Video Alzheimer's Toll On The Family Actor David Hyde Pierce talks about the devastating effect that Alzheimer's has on the family and the importance of spreading awareness during an election year. Maggie Rodriguez reports.
-
Video HealthWatch Meg Oliver reports that yoga may help women deal with menopause; turning the TV off may help your kids stay thin; and electrical stimulation may help fight Alzheimer's disease.
-
Video Eye To Eye: Alzheimer's Carol Daly, 65, describes to Dr. Jon LaPook what daily life is like with Alzheimer's. Her husband, a former cop, says the disease is the most difficult thing he's ever had to deal with.
-
Interactive Losing Memories Facts about Alzheimer's, help for caregivers and a look at sufferers who've put the disease in the spotlight.
"For the vast majority of Alzheimer's patients, taking these drugs is probably not a worthwhile risk," said Clive Ballard, the paper's lead author, of the Wolfson Centre for Age-Related Diseases at King's College London.
"Would I want to take a drug that slightly reduced my aggression but doubled my risk of dying? I'm not sure I would," Ballard said.
The research was published Friday in the medical journal Lancet Neurology.
Alzheimer's disease is the most common cause of dementia and causes symptoms including aggression, delusions and hallucinations. Previous studies have shown anti-psychotic drugs, which can help control the aggression and hallucinations for a few months raise the risk of death in older patients with dementia. There are other side effects, including respiratory problems and stroke.
Ballard and colleagues followed 165 patients aged 67 to 100 years with moderate to severe Alzheimer's disease from 2001 to 2004 in Britain. Half continued taking their anti-psychotic drugs, which included Risperdal, Thorazine and Stelazine. The other half got placebos.
Of the 83 receiving drugs, 39 were dead after a year. Of the 82 taking fake pills, 27 were dead after a year. Most deaths in both groups were due to pneumonia.
After two years, 46 percent of Alzheimer's patients taking the anti-psychotics were alive, versus 71 percent of those not on the drugs. After three years, only 30 percent of patients on the drugs were alive, versus 59 percent of those not taking drugs.
In the United Kingdom and the United States, guidelines advise doctors to use anti-psychotic drugs cautiously and temporarily. But in many nursing homes in Europe and North America, up to 60 percent of patients with dementia are routinely given the drugs for one to two years.
"The drug regimen for any person with Alzheimer's needs to be personalized," said William Thies of the Alzheimer's Association in the U.S. Thies was not connected to the study. "At some points, some people will be better off with no medication."
Simon Lovestone of the Institute of Psychiatry at King's College in London said psychiatrists should try environmental or behavioral therapies instead of anti-psychotics.
Experts aren't sure how the anti-psychotics increase patients' risk of dying. But they think the drugs could be damaging to the brain and their sedative effects make patients less able to exercise and more susceptible to deadly infections.
The study was paid for by the U.K. Alzheimer's Research Trust. Ballard reported receiving grants from various pharmaceutical companies which make drugs used to treat Alzheimer's patients.
© MMIX The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.
Best-selling author Mitch Albom on his first nonfiction work since "Tuesdays with Morrie."





- 1
- 2
- next
See all 29 CommentsAhh, gee, I forgot wat i wz gna pssst.
Families must weigh the pros and cons. As an individual in the medical field, it''s risk is valid. It is very difficult to cope at times for the families of people with Alzheimers and dementia; due to their aggitation. It''s a miracle when the drug begins to help.
NO ONE says that ALL patients should get anti-psychotic meds for Alzheimer''s. Probably, VERY few should get them, and then LATE in the process and then only by clinicians specializing in Alzheimer''s. However, a trial of giving them for marked agitation/aggression (and a "trial" implies that the meds are then stopped and the behavior between the two compared) will do no harm.
Leaving patients on any medication without a good reason is always wrong. Patients simply don''t do on "auto-pilot".
Withholding medication because of a ridiculously small study is likewise wrong.
Refusing to *try* a medication that an HCP with extensive experience suggests, based on what happened to ANOTHER patient is also inappropriate. Even if you believed that this study proved something - I don''t - IF one of this class medication provides a potential benefit and no short term risk (this study does not show any short term risk) there is no reason to withhold it.
That all said, just because this study is so under-powered as to be of little help, does NOT mean it''s wrong.
NO ONE says that ALL patients should get anti-psychotic meds for Alzheimer''s. Probably, VERY few should get them, and then LATE in the process and then only by clinicians specializing in Alzheimer''s. However, a trial of giving them for marked agitation/aggression (and a "trial" implies that the meds are then stopped and the behavior between the two compared) will do no harm.
Leaving patients on any medication without a good reason is always wrong. Patients simply don''t do on "auto-pilot".
Withholding medication because of a ridiculously small study is likewise wrong.
Refusing to *try* a medication that an HCP with extensive experience suggests, based on what happened to ANOTHER patient is also inappropriate. Even if you believed that this study proved something - I don''t - IF one of this class medication provides a potential benefit and no short term risk (this study does not show any short term risk) there is no reason to withhold it.
That all said, just because this study is so under-powered as to be of little help, does NOT mean it''s wrong.
This "study" is so small as to be (almost) statistically meaningless. I am truly amazed that Lancet would touch it with a ten foot (3m) pole.
This "study" is so small as to be (almost) statistically meaningless. I am truly amazed that Lancet would touch it with a ten foot (3m) pole.
(1) I know of no validated way to MEASURE quality of life in Alzheimer patients, but presumably the more functional the patient is, the better. I know of no evidence that these widely used medications don''t improve function. My experience is that they do. They also improve the safety of care-givers while avoiding restraints.
(2)It is exceptionally rare that an Alzheimer''s patient is treated by a psychiatrist. So we are mixing apples and oranges.
(3) Failure to accept that most mental illness is of organic origin predates MY medical training (i.e. 1978) and there is plenty of evidence that (best example) SSRI''s are very effective despite having no effect other than changing the behavior of neurotransmitters. That said, there is a kernel of truth to his comment - we do NOT have any anti-psychotic drugs that work with the specificity of SSRI''s.
(4) There is no evidence that I know of regarding respiratory depression with anti-psychotic medications.
(5) The REASON to patent a drug is to make money. If there is a plant out there that reverses dementia. and is not patented, then it is available to all. PLEASE tell us what this plant is!
(1) I know of no validated way to MEASURE quality of life in Alzheimer patients, but presumably the more functional the patient is, the better. I know of no evidence that these widely used medications don''t improve function. My experience is that they do. They also improve the safety of care-givers while avoiding restraints.
(2)It is exceptionally rare that an Alzheimer''s patient is treated by a psychiatrist. So we are mixing apples and oranges.
(3) Failure to accept that most mental illness is of organic origin predates MY medical training (i.e. 1978) and there is plenty of evidence that (best example) SSRI''s are very effective despite having no effect other than changing the behavior of neurotransmitters. That said, there is a kernel of truth to his comment - we do NOT have any anti-psychotic drugs that work with the specificity of SSRI''s.
(4) There is no evidence that I know of regarding respiratory depression with anti-psychotic medications.
(5) The REASON to patent a drug is to make money. If there is a plant out there that reverses dementia. and is not patented, then it is available to all. PLEASE tell us what this plant is!
The funny part is that it is becoming obvious to everyone except the shrinks that their drug pushing is the wrong approach but that is all they are able to offer. They are still clueless about causes and cures and a lot of the research is on the wrong track. They are doing the same old gambit. Find drugs to mask the symptoms but heaven forbid that they actually find a way to cure someone.
There are known compounds that have immediately reversed the dementia but only for a short time. Unfortunately I have seen NO research to extend the reversal or actually make the person permanently and stably cured.
I even know of one drug company that has tried to patent a plant used for millennia so that no one else has incentive to try it for Alzheimer''s
- 1
- 2
- next
See all 29 Comments